Survodutide(10mg*10vials)

Survodutide (also known as BI 456906) is an investigational synthetic peptide drug designed as a dual receptor agonist that targets both the glucagon-like peptide‑1 (GLP‑1) receptor and the glucagon receptor. This dual mechanism aims to provide comprehensive metabolic benefits by simultaneously reducing appetite, improving blood sugar control, and increasing energy expenditure. �

As a once‑weekly injectable peptide under clinical development, Survodutide has shown promising results in clinical trials for significant weight loss and metabolic improvements, including reduction in liver fat and potential benefits in metabolic dysfunction‑associated steatohepatitis (MASH)—a metabolic liver disease. �

Survodutide is not yet approved for general medical use and remains under investigation; it is primarily studied in research or clinical trial settings. �